close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abeona Therapeutics Inc. - Common Stock (NQ:ABEO)

5.700 -0.120 (-2.06%)
Streaming Delayed Price Updated: 10:57 AM EDT, Sep 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 273,891
Open 5.820
Bid (Size) 5.690 (700)
Ask (Size) 5.700 (300)
Prev. Close 5.820
Today's Range 5.695 - 5.900
52wk Range 4.000 - 7.650
Shares Outstanding 54,191,361
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright ↗
Abeona Therapeutics (NASDAQ:ABEO) highlighted the early commercial progress of ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB),... 
Via MarketBeat

Performance

YTD
+7.3%
+7.3%
1 Month
-5.9%
-5.9%
3 Month
-0.3%
-0.3%
6 Month
+31.6%
+31.6%
1 Year
+4.0%
+4.0%

More News

Read More
News headline image
Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum ↗
Via MarketBeat
News headline image
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
From Pomerantz LLP
Via GlobeNewswire
News headline image
ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona (ABEO) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Abeona Therapeutics Q2 2026 Earnings Call Transcript ↗
Via Benzinga
Topics Earnings
News headline image
Abeona Therapeutics Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona (ABEO) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Abeona Therapeutics Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Abeona Reports Strong Q1 Revenue, Expands Treatment Center Network ↗
Via Benzinga

Frequently Asked Questions

Is Abeona Therapeutics Inc. - Common Stock publicly traded?
Yes, Abeona Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Abeona Therapeutics Inc. - Common Stock trade on?
Abeona Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Abeona Therapeutics Inc. - Common Stock?
The ticker symbol for Abeona Therapeutics Inc. - Common Stock is ABEO on the Nasdaq Stock Market
What is the current price of Abeona Therapeutics Inc. - Common Stock?
The current price of Abeona Therapeutics Inc. - Common Stock is 5.700
When was Abeona Therapeutics Inc. - Common Stock last traded?
The last trade of Abeona Therapeutics Inc. - Common Stock was at 09/23/26 10:57 AM ET
What is the market capitalization of Abeona Therapeutics Inc. - Common Stock?
The market capitalization of Abeona Therapeutics Inc. - Common Stock is 308.89M
How many shares of Abeona Therapeutics Inc. - Common Stock are outstanding?
Abeona Therapeutics Inc. - Common Stock has 309M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.